Lipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1: a novel postbiotic that reduces fat deposition via IGF-1 pathway

Obesity and its related metabolic disorders, such as diabetes and cardiovascular disease, are major risk factors for morbidity and mortality in the world population. In this context, supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis BPL1 (CECT8145) has been shown to ameliorate obesity biomarkers. Analyzing the basis of this observation and using the pre-clinical model Caenorhabditis elegans, we have found that lipoteichoic acid (LTA) of BPL1 is responsible for its fat-reducing properties and that this attribute is preserved under hyperglycaemic conditions. This fat-reducing capacity of both BPL1 and LTA-BPL1 is abolished under glucose restriction, as a result of changes in LTA chemical composition. Moreover, we have demonstrated that LTA exerts this function through the IGF-1 pathway, as does BPL1 strain. These results open the possibility of using LTA as a novel postbiotic, whose beneficial properties can be applied therapeutically and/or preventively in metabolic syndrome and diabetes-related disorders.

Automated summary

The probiotic strain Bifidobacterium animalis subsp. lactis BPL1 with its lipoteichoic acid (LTA) has shown to ameliorate obesity biomarkers, even under hyperglycemic conditions. However, this fat-reducing capacity is abolished under glucose restriction due to changes in LTA chemical composition. It has been demonstrated that LTA exerts fat-reducing function through the IGF-1 pathway, similar to the BPL1 strain, suggesting the potential therapeutic and preventive applications of LTA as a novel postbiotic in metabolic syndrome and diabetes-related disorders.